Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tyra Biosciences’ 10-K can stretch beyond 200 pages of R&D detail, clinical-trial tables, and complex royalty clauses—daunting for even seasoned biotech investors. If you came here looking for Tyra Biosciences insider trading Form 4 transactions or need the Tyra Biosciences quarterly earnings report 10-Q filing, you already know the challenge: crucial data is scattered across multiple forms, each released at different times.
Stock Titan solves this problem. Our AI reads every submission the moment it hits EDGAR and delivers Tyra Biosciences SEC filings explained simply. Get AI-powered summaries that pull out runway length, trial milestones, and collaboration terms. Real-time alerts surface Tyra Biosciences Form 4 insider transactions real-time, while side-by-side views make Tyra Biosciences earnings report filing analysis painless. It’s all part of understanding Tyra Biosciences SEC documents with AI—no pharmacology PhD required.
The platform covers every disclosure type investors track: the Tyra Biosciences annual report 10-K simplified highlights clinical risks; 10-Qs map quarter-over-quarter cash burn; 8-Ks flag trial read-outs, giving you Tyra Biosciences 8-K material events explained minutes after filing. Looking for governance details? Access the full Tyra Biosciences proxy statement executive compensation. Want to monitor management confidence? Drill into Tyra Biosciences executive stock transactions Form 4. From S-3 shelf registrations that hint at future capital raises to Section 16 filings that reveal insider sentiment, Stock Titan provides the complete picture—updated continuously and distilled into clear, actionable insights.
iShares BB Rated Corporate Bond ETF, a series of iShares Trust, filed its routine Form NPORT-P for the monthly period ended 30-Apr-2025.
The fund reported total assets of $286.0 million, liabilities of $81.6 million, and net assets of $204.4 million. No borrowings were outstanding and no controlled foreign corporations were used. Cash and cash equivalents not otherwise disclosed totaled $0.20 million.
Interest-rate DV01 exposure in U.S. dollars was modest, led by the 5-year bucket at $26.96 thousand; a 100-bp parallel shift (DV100) would change portfolio value by $5.17 million in the 5-year tenor. Credit-spread sensitivity shows the portfolio is predominately non-investment-grade, with a 5-year CS01 of $55.35 thousand.
The fund is active in securities lending: across 20 counterparties, securities on loan totaled roughly $38.8 million (≈19% of net assets). Largest borrowers include Barclays Bank plc (~$9.0 m), BNP Paribas Prime Brokerage (~$7.25 m) and RBC Capital Markets (~$6.30 m). The filing indicates that some counterparties provided non-cash collateral, though exact amounts were not disclosed.
No preferred stock is outstanding, and the filing does not indicate that this will be the fund’s final NPORT-P submission.
Tyra Biosciences, Inc. (TYRA) – Form 4 insider transaction
Director Gilla Kaplan filed a Form 4 disclosing two open-market sales of the company’s common stock.
- 06/17/2025: Sold 10 shares at $10.35 each.
- 06/18/2025: Sold 9,568 shares at a $9.7822 weighted-average price (individual trades ranged from $9.55 to $9.93).
After these transactions, Kaplan’s direct beneficial ownership stands at 28,231 shares. No derivative securities were involved, and the filing does not reference any 10b5-1 trading plan. The document was signed by Attorney-in-Fact Ali D. Fawaz on 06/20/2025.
FAQ
What is the current stock price of Tyra Biosciences (TYRA)?
What is the market cap of Tyra Biosciences (TYRA)?
What is the core focus of Tyra Biosciences?
How does the SNÅP platform contribute to the company’s drug development?
What is TYRA-300 and in which indications is it being evaluated?
How does Tyra Biosciences address the issue of acquired resistance in cancer therapies?
What sets Tyra Biosciences apart from other biotechnology companies?
What are the strategic benefits of developing therapies for both oncology and skeletal dysplasias?
How does Tyra Biosciences ensure the durability and relevance of its clinical programs?
What common challenges in drug development does Tyra Biosciences aim to overcome?
